Trials / Completed
CompletedNCT03976518
Atezolizumab in Advanced Non-small Cell Lung Cancer With Rare Histologies (CHANCE Trial)
Phase II, Open-label Study of Atezolizumab in a Cohort of Pretreated, Advanced Non-small Cell Lung Cancer (NSCLC) Patients With Rare Histological Subtypes (CHANCE Trial).
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 43 (actual)
- Sponsor
- Gruppo Oncologico Italiano di Ricerca Clinica · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is aimed to explore the antitumor activity and the safety profile of atezolizumab in pretreated advanced NSCLC patients with rare histological subtypes.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Atezolizumab | Atezolizumab will be administered on Day 1 every 21 days (+/- 3 days). |
Timeline
- Start date
- 2019-05-07
- Primary completion
- 2024-02-12
- Completion
- 2024-02-12
- First posted
- 2019-06-06
- Last updated
- 2024-03-01
Locations
10 sites across 1 country: Italy
Source: ClinicalTrials.gov record NCT03976518. Inclusion in this directory is not an endorsement.